Healwell AI Inc.

OTCPK:HWAI.F Stock Report

Market Cap: US$197.0m

Healwell AI Valuation

Is HWAI.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HWAI.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HWAI.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HWAI.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HWAI.F?

Key metric: As HWAI.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HWAI.F. This is calculated by dividing HWAI.F's market cap by their current revenue.
What is HWAI.F's PS Ratio?
PS Ratio10.7x
SalesCA$25.69m
Market CapCA$276.10m

Price to Sales Ratio vs Peers

How does HWAI.F's PS Ratio compare to its peers?

The above table shows the PS ratio for HWAI.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.6x
FLGT Fulgent Genetics
2x12.7%US$552.7m
NUTX Nutex Health
0.7x12.6%US$200.7m
EUDA EUDA Health Holdings
40.5x61.5%US$154.4m
BDSX Biodesix
3.2x19.7%US$207.3m
HWAI.F Healwell AI
10.7x49.2%US$276.1m

Price-To-Sales vs Peers: HWAI.F is good value based on its Price-To-Sales Ratio (10.7x) compared to the peer average (11.6x).

Price to Sales Ratio vs Industry

How does HWAI.F's PS Ratio compare vs other companies in the US Healthcare Industry?

30 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$79.51b
CVS CVS Health
0.2x4.5%US$75.45b
COR Cencora
0.2x6.5%US$48.26b
CNC Centene
0.2x5.5%US$30.26b
HWAI.F 10.7xIndustry Avg. 1.1xNo. of Companies30PS012345+
30 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HWAI.F is expensive based on its Price-To-Sales Ratio (10.7x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is HWAI.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HWAI.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.7x
Fair PS Ratio5.1x

Price-To-Sales vs Fair Ratio: HWAI.F is expensive based on its Price-To-Sales Ratio (10.7x) compared to the estimated Fair Price-To-Sales Ratio (5.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HWAI.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.13
US$2.59
+129.5%
19.3%US$3.58US$1.79n/a8
Nov ’25US$0.95
US$2.63
+177.6%
18.7%US$3.59US$1.80n/a8
Oct ’25US$1.10
US$2.85
+159.3%
16.4%US$3.65US$2.19n/a5
Sep ’25US$1.39
US$2.85
+105.2%
16.4%US$3.65US$2.19n/a5
Aug ’25US$1.52
US$2.85
+87.1%
16.4%US$3.64US$2.18n/a5
Jul ’25US$1.81
US$2.85
+57.3%
16.4%US$3.64US$2.18n/a5
Jun ’25US$1.47
US$1.64
+11.6%
8.7%US$1.83US$1.43n/a4
May ’25US$1.08
US$0.99
-8.4%
12.8%US$1.11US$0.81n/a4
Apr ’25US$0.67
US$0.95
+41.6%
12.9%US$1.11US$0.82n/a3
Mar ’25US$0.80
US$0.95
+19.2%
12.9%US$1.11US$0.82n/a3
Feb ’25US$0.49
US$0.97
+96.9%
15.4%US$1.12US$0.82n/a2
Jan ’25US$0.55
US$0.98
+78.6%
15.4%US$1.13US$0.83n/a2
Dec ’24US$0.73
US$0.95
+30.8%
15.4%US$1.10US$0.80n/a2
Mar ’24n/a
US$0.90
0%
16.7%US$1.05US$0.75US$0.802
Feb ’24n/a
US$0.90
0%
16.7%US$1.05US$0.75US$0.492
Jan ’24n/a
US$0.90
0%
16.7%US$1.05US$0.75US$0.552
Dec ’23n/a
US$0.90
0%
16.7%US$1.05US$0.75US$0.732
Nov ’23n/a
US$1.40
0%
16.7%US$1.64US$1.17US$0.552

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.93

7D

1.4%

1Y

-15.0%

Lantheus Holdings

US$6.2b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

7D

4.4%

1Y

28.9%

Sensus Healthcare

US$141.1m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

7D

-3.8%

1Y

252.5%